NASDAQ:OBLNObalon Therapeutics Stock Price, Forecast & News

Obalon Therapeutics' stock was trading at $1.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OBLN shares have decreased by 8.1% and is now trading at $0.9556. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Obalon Therapeutics.

Obalon Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, June 5th 2020. View our earnings forecast for Obalon Therapeutics.

Obalon Therapeutics Inc (NASDAQ:OBLN) released its quarterly earnings results on Thursday, February, 27th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.06. The company had revenue of $0.79 million for the quarter. Obalon Therapeutics had a negative return on equity of 186.35% and a negative net margin of 721.61%. View Obalon Therapeutics' earnings history.

Shares of Obalon Therapeutics reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

2 Wall Street analysts have issued 1-year price objectives for Obalon Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Obalon Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 946.5% from the stock's current price. View analysts' price targets for Obalon Therapeutics.

Press coverage about OBLN stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Obalon Therapeutics earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near term. View the latest news aboutObalon Therapeutics.

Some companies that are related to Obalon Therapeutics include Invo Bioscience (IVOB), Atossa Genetics (ATOS), DarioHealth (DRIO), Biostage (BSTG), Delcath Systems (DCTH), Interpace Diagnostics Group (IDXG), Titan Medical (TMDI), Endologix (ELGX), Avinger (AVGR), Hypertension Diagnostics (HDII), Dynatronics (DYNT), Sintx Technologies (SINT), Invivo Therapeutics (NVIV), Encision (ECIA) and Lianluo Smart (LLIT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Opko Health (OPK), Inpixon (INPX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Zynerba Pharmaceuticals (ZYNE), Co-Diagnostics (CODX) and Corbus Pharmaceuticals (CRBP).

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

Obalon Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Sabby Management LLC (2.23%). Company insiders that own Obalon Therapeutics stock include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View institutional ownership trends for Obalon Therapeutics.

OBLN stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View insider buying and selling activity for Obalon Therapeutics.

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OBLN stock can currently be purchased for approximately $0.96.

Obalon Therapeutics has a market capitalization of $7.39 million and generates $3.28 million in revenue each year. Obalon Therapeutics employs 100 workers across the globe.

The official website for Obalon Therapeutics is www.obalon.com.

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]